Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in  NPM1  mutated acute myeloid leukemia

Nikhil Patkar; Rohan Kodgule; Chinmayee Kakirde; Goutham Raval; Prasanna Bhanshe; Swapnali Joshi; Shruti Chaudhary; Y. Badrinath; Sitaram Ghoghale; Shraddha Kadechkar; Syed Hasan Khizer; Sadhana Kannan; Dhanalaxmi Shetty; Anant Gokarn; Sachin Punatkar; Hasmukh Jain; Bhausaheb Bagal; Hari Menon; Manju Sengar; Navin Khattry; Prashant Tembhare; Papagudi Subramanian; Sumeet Gujral

doi:10.18632/oncotarget.26610

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

PDF | How to cite

Oncotarget. 2019; 10:617-617. https://doi.org/10.18632/oncotarget.26610

Metrics: PDF 1760 views | ?

Nikhil Patkar^1,*, Rohan Kodgule^1,5,*, Chinmayee Kakirde¹, Goutham Raval¹, Prasanna Bhanshe¹, Swapnali Joshi¹, Shruti Chaudhary¹, Y. Badrinath¹, Sitaram Ghoghale¹, Shraddha Kadechkar¹, Syed Hasan Khizer², Sadhana Kannan³, Dhanalaxmi Shetty⁴, Anant Gokarn², Sachin Punatkar², Hasmukh Jain², Bhausaheb Bagal², Hari Menon⁶, Manju Sengar², Navin Khattry², Prashant Tembhare¹, Papagudi Subramanian¹ and Sumeet Gujral¹

¹ Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India
² Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
³ Biostatistics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
⁴ Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
⁵ Homi Bhabha National Institute, Training School Complex, Mumbai, India
⁶ Haemato-Oncology, CyteCare Cancer Hospital, Bangalore, India
^* These authors contributed equally to this work

Published: January 15, 2019

This article has been corrected: The correct Funding information is given below:

FUNDING

This work was supported by the Wellcome Trust/DBT India Alliance Fellowship [grant number IA/CPHI/14/1/501485] awarded to Dr Nikhil Patkar. Initial part of the study (8 colour FCM) was funded by a Lady Tata Memorial Trust Grant awarded to Prof Navin Khattry.

Original article: Oncotarget. 2018; 9:36613-36624. DOI: https://doi.org/10.18632/oncotarget.26400.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26610

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia